Data from preclinical and clinical trials of BAY 86-9766 (formerly known as RDEA119) will be presented at the 22nd EORTC-NCI-AACR Symposium, organized from 16 – 19 November 2010, in Berlin, Germany.

Data from preclinical and clinical trials of BAY 86-9766 (formerly known as RDEA119) will be presented at the 22nd EORTC?NCI?AACR symposium on “Molecular Targets and Cancer Therapeutics” organized from November 16 – 19, in Berlin, Germany.

BAY 86-9766 is a mitogen-activated ERK kinase (MEK) inhibitor licensed to and being developed by Bayer HealthCare AG.

The results of a multi-center, Phase 1, monotherapy, dose-escalation study of BAY 86-9766 in advanced cancer patients will be presented by Colin Weekes, MD, PhD, Assistant Professor, Division of Medical Oncology at the University of Colorado School of Medicine. The principal investigators for this study included Dr. Weekes, Daniel D. Von Hoff, MD, Professor of Medicine at the University of Arizona School of Medicine and Executive Vice President of the Translational Genomics Research Institute (TGen), and Alex Adjei, MD, PhD, Professor and Chair, Department of Medicine at the Roswell Park Cancer Institute. In addition, data from preclinical studies of BAY 86-9766, demonstrating its potential for administration in combination with other anti-cancer agents will be presented by Bayer.

Port Worthy
Axplora

“Based on the good tolerability and impressive number of patients who achieved stable disease in this Phase 1 monotherapy trial in refractory patients with advanced solid tumors, we believe BAY 86-9766 has the potential to be a clinically important drug in the treatment of patients across multiple tumor types,” said Dr. Adjei. “These monotherapy results support our ongoing Phase 1/2 study of BAY 86-9766 in combination with sorafenib at the maximum tolerated dose defined in this trial and the continued research by Bayer Healthcare on this important new targeted therapy.”

Advertisement #3

For more information:

[1] A Multi-Center Phase 1, Dose-Escalation Trial to Determine the Safety and Pharmacokinetics/Pharmacodynamics of BAY 86-9766 (RDEA119), a MEK Inhibitor, in Advanced Cancer Patients (Abstract: #368; Thursday, November 18, 2010 from 12:00 PM ? 2:40 PM CET)
[2] Combination of PI3K Inhibitor BAY 80-6946 with Allosteric MEK Inhibitor BAY 86-9766 (RDEA119) and with Erlotinib for the Treatment of Non-Small Cell Lung Cancer (Abstract #138; Wednesday, November 17, 2010 from 12:00 PM ? 2:40 PM CET)
[3] Combination of PI3K Inhibitor BAY 80-6946 with Allosteric MEK Inhibitor BAY 86-9766 (RDEA119), a Promising Approach for the Treatment of Colorectal Cancers (Abstracy #140; Wednesday, November 17, 2010 from 12:00 PM ? 2:40 PM CET)
[4] Allosteric MEK Inhibitor BAY 86-9766 (RDEA119) Shows Anti-Tumor Efficacy in Mono- and Combination Therapy in Models of Hepatocellular Carcinoma and Pancreatic Cancer (Abstract #151; Wednesday, November 17, 2010 from 12:00 PM ? 2:40 PM CET).

Copyright ? 2010 Sunvalley Communication. All rights reserved.
Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.

Byondis
Advertisement #5